MX2020012103A - Proteina de fusion fviii mejorada y uso de la misma. - Google Patents
Proteina de fusion fviii mejorada y uso de la misma.Info
- Publication number
- MX2020012103A MX2020012103A MX2020012103A MX2020012103A MX2020012103A MX 2020012103 A MX2020012103 A MX 2020012103A MX 2020012103 A MX2020012103 A MX 2020012103A MX 2020012103 A MX2020012103 A MX 2020012103A MX 2020012103 A MX2020012103 A MX 2020012103A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- polyalkylene glycol
- life
- fviii fusion
- factor viii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810481941 | 2018-05-18 | ||
| PCT/CN2019/087156 WO2019219049A1 (zh) | 2018-05-18 | 2019-05-16 | 改进的fviii融合蛋白及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012103A true MX2020012103A (es) | 2021-01-29 |
Family
ID=68539524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012103A MX2020012103A (es) | 2018-05-18 | 2019-05-16 | Proteina de fusion fviii mejorada y uso de la misma. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12440572B2 (enExample) |
| EP (1) | EP3816181A4 (enExample) |
| JP (2) | JP2021530437A (enExample) |
| KR (1) | KR102575788B1 (enExample) |
| CN (2) | CN113039200B (enExample) |
| BR (1) | BR112020023168A2 (enExample) |
| MA (1) | MA53020A (enExample) |
| MX (1) | MX2020012103A (enExample) |
| WO (1) | WO2019219049A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4534563A1 (en) | 2022-05-25 | 2025-04-09 | Jiangsu Gensciences Inc. | Fviii fusion protein conjugate having extended half-life and use thereof |
| CN116284411B (zh) * | 2023-02-03 | 2024-02-13 | 北京基科晟斯医药科技有限公司 | 抗培重组人凝血因子VIII-Fc融合蛋白的抗体及其应用 |
| CN116036244B (zh) * | 2023-02-24 | 2023-09-19 | 北京基科晟斯医药科技有限公司 | 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4818679A (en) | 1985-02-19 | 1989-04-04 | The Trustees Of Columbia University In The City Of New York | Method for recovering mutant cells |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| EP1003894A2 (en) * | 1997-07-18 | 2000-05-31 | Chiron Corporation | Lentiviral vectors |
| SI1824988T1 (sl) | 2004-11-12 | 2017-11-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
| EP1891231A4 (en) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | GLYCOPEGYLATED FACTOR IX |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| US20120121613A1 (en) | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
| EP2536754A1 (en) * | 2010-02-16 | 2012-12-26 | Novo Nordisk A/S | Factor viii fusion protein |
| EP2536753B1 (en) | 2010-02-16 | 2017-12-20 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
| GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| HK1198541A1 (en) | 2011-10-18 | 2015-05-15 | Csl Limited | Method for improving the stability of purified factor viii after reconstitution |
| CN103172745A (zh) | 2011-12-21 | 2013-06-26 | 北京韩美药品有限公司 | 包含免疫球蛋白Fc片段的长效人内皮抑素 |
| EA035323B1 (ru) | 2012-01-12 | 2020-05-28 | Биовератив Терапьютикс Инк. | Полипептиды химерного фактора viii и их применение |
| WO2014008480A2 (en) * | 2012-07-06 | 2014-01-09 | Biogen Idec Ma Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
| CN104519912A (zh) | 2012-08-13 | 2015-04-15 | 诺和诺德A/S（股份有限公司） | 液体因子viii制剂 |
| WO2014100913A1 (en) | 2012-12-24 | 2014-07-03 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
| DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| CN103539860B (zh) | 2013-11-01 | 2014-12-03 | 广州优联康医药科技有限公司 | 一种长效重组人促卵泡激素融合蛋白 |
| SG11201805497QA (en) * | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
| JP6877469B2 (ja) | 2016-06-24 | 2021-05-26 | モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
-
2019
- 2019-05-16 MA MA053020A patent/MA53020A/fr unknown
- 2019-05-16 CN CN201980033170.0A patent/CN113039200B/zh active Active
- 2019-05-16 EP EP19804136.0A patent/EP3816181A4/en active Pending
- 2019-05-16 WO PCT/CN2019/087156 patent/WO2019219049A1/zh not_active Ceased
- 2019-05-16 KR KR1020207034852A patent/KR102575788B1/ko active Active
- 2019-05-16 US US17/055,403 patent/US12440572B2/en active Active
- 2019-05-16 CN CN202310860049.3A patent/CN117467019A/zh active Pending
- 2019-05-16 JP JP2020564649A patent/JP2021530437A/ja active Pending
- 2019-05-16 MX MX2020012103A patent/MX2020012103A/es unknown
- 2019-05-16 BR BR112020023168-1A patent/BR112020023168A2/pt unknown
-
2023
- 2023-04-20 JP JP2023069317A patent/JP7492780B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113039200B (zh) | 2023-07-25 |
| KR20210005248A (ko) | 2021-01-13 |
| BR112020023168A2 (pt) | 2021-02-09 |
| JP2023093634A (ja) | 2023-07-04 |
| EP3816181A4 (en) | 2022-04-20 |
| CN117467019A (zh) | 2024-01-30 |
| MA53020A (fr) | 2021-05-05 |
| KR102575788B1 (ko) | 2023-09-08 |
| EP3816181A1 (en) | 2021-05-05 |
| JP7492780B2 (ja) | 2024-05-30 |
| CN113039200A (zh) | 2021-06-25 |
| US12440572B2 (en) | 2025-10-14 |
| US20210361775A1 (en) | 2021-11-25 |
| WO2019219049A1 (zh) | 2019-11-21 |
| JP2021530437A (ja) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002250A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520) | |
| MX2021003475A (es) | Metodos de purificacion de proteinas. | |
| CY1122494T1 (el) | Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων | |
| EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
| SA522432917B1 (ar) | ميوتينات إنترليوكين-21 وطرق العلاج | |
| MX2024014691A (es) | Enlazadores de conjugacion mejorados | |
| ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
| MX2022006760A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
| BR112018075653A2 (pt) | anticorpos anti-b7-h3 e conjugados anticorpo fármaco | |
| BR112018075649A2 (pt) | anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo | |
| CY1119106T1 (el) | Αντισωματα εναντι masp-2 | |
| MX2020012103A (es) | Proteina de fusion fviii mejorada y uso de la misma. | |
| BR112020015308A8 (pt) | Proteínas f de rsv estabilizadas e usos das mesmas | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου | |
| CY1119219T1 (el) | Anti-ceacam5 αντισωματα και χρησεις αυτων | |
| EA201991168A1 (ru) | Белок, связывающий простатический специфический мембранный антиген | |
| EA201690744A1 (ru) | Конъюгаты белок-полимер-лекарственное средство | |
| DE60232577D1 (de) | Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential | |
| WO2016210365A3 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
| EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
| EA200971129A1 (ru) | Циклические пептиды-антагонисты cxcr4 | |
| BR112021025699A2 (pt) | Anticorpos anti-mesotelina e imunoconjugados dos mesmos |